# 本週健康新聞聚焦全球重大發展。

*biotech · news · 2026-05-29 · Devdiscourse*

## Key points

- 根據非洲疾病控制中心，非洲伊波拉疫情應對的資金大幅減少。
- Bristol Myers Squibb報告其治療方案在持續研究中延緩多發性骨髓瘤的進展。
- 美國FDA指出Dabur India製造設施存在重大數據完整性問題。
- CVS Health已恢復對Eli Lilly減重藥物Zepbound的保險覆蓋。

This week's health news highlights major developments across the globe. Funding for Africa's Ebola outbreak has seen a significant decrease, posing challenges in containment efforts, as highlighted by the Africa CDC. Meanwhile, Bristol Myers Squibb reports positive results in delaying disease progression among myeloma patients, demonstrating promise in ongoing treatment advancements. The U.S. FDA has raised significant concerns regarding data integrity issues at Dabur India's facility, following a recent inspection. Dabur faces scrutiny given its position as a leading supplier of Ayurvedic and consumer health products. This challenge underscores the importance of compliance in manufacturing processes to ensure consumer safety and trust. In pharmaceutical news, CVS Health has decided to reinstate coverage for Eli Lilly's weight-loss injection, Zepbound, marking a strategic shift amidst pharmaceutical market dynamics. As the global community continues to navigate health challenges, the European Medicines Agency is proactively exploring treatments for emerging viruses, such as hantavirus, ensuring preparedness in public health responses. (With inputs from agencies.)

**Companies:** Bristol Myers Squibb, CVS Health, Dabur India
**Countries:** United States, India, European Union

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3925993-evolving-health-landscape-key-developments-in-global-health-policies)

---

Canonical: https://newsio.io/zh-TW/n/5e0b2382-520e-47a6-972e-10c8d647bcc8/bristol-myers-squibb
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works